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Abstract
Castration-resistant prostate cancer (CRPC) continues to pose a significant clinical challenge with 
new generation second line hormonal therapies affording limited improvement in disease 
outcome. As the androgen receptor (AR) remains a critical driver in CRPC, understanding the 
determinants of its transcriptional activity is important for developing new AR targeted therapies. 
FOXA1 is a key component of the AR transcriptional complex yet its role in prostate cancer 
progression and the relationship between AR and FOXA1 are not completely resolved. It is well 
established that FOXA1 levels are elevated in advanced prostate cancer and metastases. We 
mimicked these conditions by over-expressing FOXA1 in the androgen-responsive LNCaP 
prostate cancer cell line and observed a significant increase in AR genomic binding at novel 
regions that possess increased chromatin accessibility. High levels of FOXA1 resulted in increased 
proliferation at both sub-optimal and high 5α-dihydrotestosterone (DHT) concentrations. 
Immunohistochemical staining for FOXA1 in a clinical prostate cancer cohort revealed that high 
FOXA1 expression is associated with shorter time to biochemical recurrence after radical 
prostatectomy (HR 5.0, 95% CI 1.2-21.1, p=0.028), positive surgical margins and higher stage 
disease at diagnosis. The gene expression program that results from FOXA1 over-expression is 
enriched for PTEN, Wnt and other pathways typically represented in CRPC gene signatures. 
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Together these results suggest that in an androgen-depleted state, elevated levels of FOXA1 
enhance AR binding at genomic regions not normally occupied by AR, which in turn facilitates 
prostate cancer cell growth.
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Prostate cancer is the most common non-cutaneous cancer in men accounting for almost one 
third of all newly diagnosed cancers (1). The standard first line of treatment for metastatic 
prostate cancer is androgen deprivation therapy (ADT), which typically induces regression 
of the tumor. Despite a high initial response rate in nearly all cases, resistance to ADT 
occurs resulting in tumor regrowth which is termed castration-resistant prostate cancer 
(CRPC) (2). Tumors that become resistant to ADT pose a significant clinical challenge. The 
development of new hormonal therapies that target androgen biosynthesis (e.g. Abiraterone) 
or the androgen receptor directly (e.g. Enzalutamide) has produced improved outcomes for 
patients with CRPC, but they are not universally effective and responses are not durable (3, 
4). The androgen receptor (AR) remains active and critical for tumor growth in CRPC 
despite low circulating levels of androgens, but typically there are alterations in the receptor 
structure or function that allow it to retain activity despite ADT. Documented methods for 
circumvention of ADT include AR gene amplification, acquisition of mutations, genomic 
rearrangements and alternative splicing of AR (2, 5-8). An additional mechanism is altered 
interaction of AR with key transcriptional cofactors (9).
The forkhead transcription factor FOXA1 is a key member of the AR transcriptional 
complex, which has been shown to interact directly with AR through the hinge domain (10). 
FOXA1 functions primarily as a pioneer factor, binding to closed chromatin regions through 
its winged helix domain, which has a structure akin to that of linker histones. FOXA1 
association with chromatin contributes to changes in chromatin accessibility, rendering these 
regions more accessible to nuclear receptors such as AR (11), ER (12) and PR (13) . As 
such, FOXA1 plays a key role in demarcating the tissue specific binding sites of these 
nuclear receptors (14). FOXA1, expressed in the peripheral zone of the human prostate (15), 
is essential for hormone induced ductal branching and epithelial cell maturation of the 
prostate gland during puberty (16). Furthermore, FOXA1 plays a central role in AR driven 
gene expression in both the normal prostate and prostate cancers (11, 17, 18).
There are a number of conflicting reports regarding the role that FOXA1 plays in the 
progression of prostate cancer to castrate resistant disease and its expression has been 
associated with both good and poor prostate cancer patient outcome. One study suggested 
that FOXA1 mRNA levels are moderately up-regulated in primary cancer when compared to 
benign disease, but unexpectedly it was down-regulated in metastasis (19). In contrast to this 
observation, a number of immunohistochemical studies have shown that FOXA1 is a marker 
of poor outcome in prostate cancer, with high FOXA1 levels being associated with a shorter 
time to biochemical recurrence (15, 20) or prostate cancer-specific death (21). High 
Robinson et al. Page 2
Oncogene. Author manuscript; available in PMC 2015 June 11.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
expression at the protein level has also been noted in the majority (82-89%) of metastatic 
and CRPC samples (15, 22).
At the molecular level, it remains to be determined what the exact consequences of higher 
FOXA1 levels are for prostate cancer progression. Examination of AR binding events in 
CRPC cell line models and primary tissues suggests that the unique CRPC AR sites are not 
reliant upon FOXA1 (23, 24) and similarly, FOXA1 may have AR independent functions in 
CRPC (25). Despite this, FOXA1 over-expressing LNCaP prostate cancer cells exhibit 
increased migration and produce larger tumors in xenograft models (15, 26). Thus it is 
imperative to assess the consequences of elevated FOXA1 expression and the potential 
impact on AR signalling during prostate cancer progression.
In this study, we assessed the downstream effects of elevated FOXA1 levels on AR 
chromatin binding, gene expression and prostate cancer cell proliferation. We found that in 
cells expressing higher levels of FOXA1, AR makes novel chromatin associations and is 
able to drive tumor cell growth even at reduced levels of androgen, suggesting that tumors 
with higher FOXA1 levels may have a growth advantage following androgen deprivation.
Results
Higher levels of FOXA1 result in increased AR binding
Given the disputed role that elevated levels of FOXA1 play in prostate cancer, we aimed to 
examine the effects of over-expression of FOXA1 in prostate cancer cells. The LNCaP 
prostate cancer cell line was transiently transfected with a control vector or a FOXA1 
construct, which we subsequently termed ‘FOXA1 high’ cells. Western blot analysis 
confirmed increased FOXA1 levels compared to GFP control transfected cells 
(Supplementary Figure 1A). Since AR is central to both primary and castrate resistant 
prostate cancer, we initially focused on the effect of increased levels of FOXA1 upon AR 
binding. Genome wide AR binding regions were mapped in asynchronous ‘FOXA1 high’ 
versus GFP control cells and we found an almost two-fold increase in reproducible AR 
binding sites (ARBS) in ‘FOXA1 high’ cells (33,953 ARBS in control cells versus 57,155 
ARBS in ‘FOXA1 high’ cells, Supplementary Table 1). The majority (86%) of the ARBS in 
control cells were also seen in FOXA1 high cells. However, in elevated FOXA1 conditions, 
an additional 28,100 ARBS were observed (Figure 1A).
In general, there was a significant increase in AR peak strength across all sites in ‘FOXA1 
high’ cells compared to control (Figure 1B). Shared regions identified in both control and 
FOXA1 over-expressing cells have a significantly higher mean read count at the AR peak 
summit in ‘FOXA1 high’ cells (8.34 reads) compared to control (6.03 reads; Figure 1C). 
Additionally, there are a large number of sites (28,100) where an ARBS was only detected 
in ‘FOXA1 high’ cells, termed ‘gained’ sites (Figure 1C). Interestingly, the new AR binding 
sites that occur in the presence of elevated FOXA1 are regions that have some weak binding 
in control cells, implying an amplification of AR-DNA binding at suboptimal binding 
domains (mean read count 2.76 in ‘FOXA1 high’ versus 1.56 in Control cells; Figure 1C). 
Overall our data suggests a general amplification of AR binding in the presence of higher 
FOXA1 levels as illustrated by a heatmap of the shared and gained ARBS (Figure 1D) and 
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an example genomic region (Figure 1E). This phenomenon was confirmed in another AR 
driven cancer cell line model, the ERα-AR+ MDA-MB-453 cell line, which is used as a 
model of molecular apocrine breast cancer. AR ChIP-seq in ‘FOXA1 high’ MDA-MB-453 
cells also showed greater AR binding intensity than in control cells (Supplementary Figure 
2A&B and Supplementary Table 1).
Two recently published studies reported reprogramming of AR to de novo regions in the 
genome following loss of FOXA1 in LNCaP prostate cancer cells (10, 21). We performed 
hierarchical cluster analysis to compare the sites of AR occupancy in our GFP control and 
‘FOXA1 high’ LNCaP cells with those in the siControl and siFOXA1 treated LNCaP cells 
from the published studies. By directly comparing the changes that occur in AR binding in 
conditions where FOXA1 is both absent and over-expressed, we see that the ARBS 
determined in the siFOXA1 treatment group cluster separately from those in ‘FOXA1 high’ 
cells. This indicates that the novel ARBS seen in ‘FOXA1 high’ cells are not the same 
locations as the de novo AR binding seen after loss of FOXA1 (Supplementary Figure 1B & 
C).
Increase in AR Occupancy after FOXA1 over-expression is likely due to increased 
chromatin accessibility
In order to infer the mechanism behind the increased AR binding seen after FOXA1 over-
expression, we assessed whether there was a global increase in AR protein levels, but we did 
not detect an appreciable change in AR levels following FOXA1 over-expression 
(Supplementary Figure 1A). Therefore to identify alternate factors that may be redirecting 
AR to the chromatin, we conducted de novo motif analysis on the unique ARBS associated 
with FOXA1 over-expression. We found significant enrichment for motifs representing 
STAT3, SP1 and the ETS (ELF5) transcription factors (Figure 2A). We also detected a 
strong enrichment for forkhead motifs suggesting a large majority of the new ARBS may be 
directed by FOXA1 itself. Comparison of our data with previously published LNCaP 
FOXA1 ChIP-seq data (27) revealed that FOXA1 is present at a large number (37%) of the 
gained ARBS sites (Figure 2B). Therefore over-expression of FOXA1 may directly mediate 
AR binding to ‘FOXA1 high’ gained regions. This is supported by the visible but relatively 
weak FOXA1 binding at these gained AR binding regions, which one could postulate is 
increased upon FOXA1 over-expression (Supplementary Figure 3).
In an effort to identify additional regulatory mechanisms that impinge on the AR-FOXA1 
complex, we performed RIME (Rapid IMmunoprecipitation of Endogenous proteins) 
proteomic analysis (28) of each transcription factor. Three independent replicates of AR and 
two independent replicates of FOXA1 RIME were conducted. Proteins must have been 
detected in at least two replicates, but in none of the matched IgG control 
immunoprecipitations to be considered an interacting protein. This led to the identification 
of 139 AR and 236 FOXA1 interacting proteins (Supplementary Table 2). In total, 56 
proteins interact with both AR and FOXA1 in our data. Pathway analysis of these common 
interacting partners revealed a highly significant enrichment for proteins involved in 
chromatin remodelling, in particular for the locus control region (LCR)-associated 
remodelling complex, LARC (Figure 2C, Supplementary Table 2). LARC is a complex that 
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controls accessibility of regulatory DNA sequences situated many kilobases away from their 
cognate promoters (29) that AR and FOXA1 co-occupy. A number of these proteins have 
been validated in other studies to interact with AR (30-33). FOXA1’s intrinsic pioneer factor 
function coupled with its interaction with a large number of histone modifying enzymes 
suggests that increased binding of AR under FOXA1 high conditions may occur because of 
enhanced chromatin accessibility at these regions.
FOXA1 over-expression increases proliferation in AR-driven cancers and correlates with 
poor outcome in prostate cancer
The effect of high levels of FOXA1 on prostate cancer proliferation was assessed in AR+ 
LNCaP prostate cancer cells and our second AR-driven cancer model, the MDA-MB-453 
molecular apocrine breast cancer cell line. Western blot analysis confirmed FOXA1 over-
expression in MDA-MB-453 cells with no alteration in AR protein levels (Supplementary 
Figure 1A). Proliferation of both cell lines was assessed following treatment with either high 
(100nM DHT) or low (0.5nM DHT) androgen concentrations, the latter to mimic androgen 
depleted conditions observed following ADT. ‘FOXA1 high’ cells exhibited significantly 
higher levels of proliferation than GFP control transfected cells at both DHT concentrations 
(Figure 3A). Interestingly, a similar effect of FOXA1 over-expression was observed in the 
MDA-MB-453 breast cancer cells following treatment with high and low doses of androgen 
(Figure 3B), suggesting that higher expression of FOXA1 enhances the growth promoting 
effects of AR in a ubiquitous, non-tissue specific manner in AR-driven cancers.
To address some of the conflicting data regarding the prognostic value of FOXA1 
expression in prostate cancer, we undertook an immunohistochemical analysis of FOXA1 in 
a tissue microarray (TMA) of 102 prostate cancer cases. Our study with a median follow up 
time of 86 months after radical prostatectomy (range 3 to 151 months) has longer follow up 
than other published studies. Examples of FOXA1 immunostaining in prostate cancer are 
shown in Figure 4 A-F. We found FOXA1 expression to be significantly higher in tumors 
compared to matched benign and normal prostate tissues (median H-score cancer = 69.44 
versus benign = 0, p value <0.0001, Supplementary Figure 4).
In evaluating the association between FOXA1 H-score and biochemical recurrence, we 
divided patients into two groups based on the first quartile given that this cut-point showed 
the most significant difference. There was a significantly higher risk of biochemical 
recurrence for patients with high FOXA1 staining (H-score >4.0, second through fourth 
quartile) compared to those with no or low FOXA1 staining, H-score ≤4.0 (HR 5.0, 95% CI 
1.2-21.1, p=0.028, Figure 4G). In particular, we noted a marked difference in the ten year 
biochemical recurrence free survival rate; 94.1% (95% CI 83.6%-100%) for patients with 
low FOXA1 staining compared to 53.6% (95% CI 42.2%-68.0%) for those with high 
FOXA1 staining. As detailed in Table 1, high FOXA1 staining also significantly correlated 
with higher pathological stage (p <0.0001) and positive surgical margins (p = 0.021), which 
are markers of poor disease outcome (Supplementary Table 3). There was no statistically 
significant evidence of an association with Gleason Score (p = 0.25). Additionally, we 
assessed whether FOXA1 predicted outcome independently of other known prostate cancer 
markers. We observed a greater than three-fold increased risk of biochemical recurrence in 
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patients with high FOXA1 staining compared to those with low staining when adjusting 
individually for pathological stage (HR: 3.60, p=0.084, n=79) Gleason Score (HR: 3.02, 
p=0.13, n=74) and PSA (HR: 4.58, p=0.039, n=76), although this was not always significant 
in these smaller samples with missing clinicopathologic data.
High FOXA1 induce a gene expression program similar to CPRC tissue signature
To elucidate the downstream effects of elevated FOXA1 expression, we conducted 
microarray analysis on Control versus ‘FOXA1 high’ asynchronous LNCaP cells. Using six 
biological replicates, we found 124 differentially regulated genes (DEG) with an FDR 
<0.05; this included 51 up-regulated and 73 down-regulated genes in ‘FOXA1 high’ cells 
(Figure 5A). The majority of these genes have an ARBS within 25kb of their start site in 
‘FOXA1 high’ cells (93/124 DEG, 75%) implying that AR may be directly regulating 
expression of these differential genes. However, these genes are not typically regulated in 
vitro by DHT in the context of normal endogenous levels of FOXA1, with only 5.6% of the 
differentially expressed genes in ‘FOXA1 high’ cells considered to be androgen-regulated in 
an independent dataset of DHT-treated LNCaP cells (34).
Pathway analysis of the ‘FOXA1 high’ differentially expressed genes (Figure 5B) revealed a 
number of networks focused on signalling pathways known to be perturbed in prostate 
cancer (PTEN null, polycomb targets and TNC targets which signal through WNT) as well 
as differentiation pathways (Trogatizalone targets, poorly differentiated carcinoma and 
mature luminal cell program). Due to the high expression of FOXA1 in CRPC and 
metastases (15, 22), we used Gene Set Enrichment Analysis to correlate the CRPC gene 
program identified by Sharma et al (24) from primary CRPC tissue with the data from our 
‘FOXA1 high’ microarray. There was a significant enrichment of the CRPC gene set in our 
data set (p value 0.018, normalized enrichment score 1.14, Figure 5C) implying that FOXA1 
may be in part responsible for the expression of a number of the genes expressed in CRPC. 
In support of this concept, others have shown that silencing of FOXA1 in LNCaP-abl cells 
(one model of CRPC) has both AR-dependent and –independent effects on cell proliferation 
(25), and that loss of FOXA1 inhibits ligand-dependent AR chromatin binding in C4-2B 
cells (another LNCaP-derived model of CRPC (23). Importantly we found that silencing of 
FOXA1 in C4-2B cells markedly inhibited their proliferative capacity (Supplementary 
Figure 5). Our data suggests that high levels of FOXA1 can drive a gene expression program 
that is similar to that seen in patients who develop castrate resistant disease, implying a 
central role for FOXA1 in the development of CRPC.
Discussion
FOXA1 is a well-established member of the AR transcription complex, where it is required 
to direct AR binding to tissue specific sites by opening up chromatin (11, 14, 17, 18). In 
addition, FOXA1 is essential for optimal proliferative capacity of AR-positive LNCaP-
derived prostate cancer cell lines (20, 25). Herein, we model for the first time the genomic 
consequences of elevated levels of FOXA1 in LNCaP prostate cancer cells and show that 
abnormally high FOXA1 levels induce a genome-wide increase in AR chromatin binding at 
29,055 “expected” genomic locations, without a concomitant increase in AR protein levels. 
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In addition to enhancement of AR binding to traditional AR regulatory elements with 
overexpression of FOXA1, there was a significant increase in AR binding at 28,100 ARBS 
that exhibited weak binding under endogenous levels of FOXA1 expression. These findings 
suggest that elevated FOXA1 levels, which are characteristic of CRPC, facilitate AR 
binding to secondary sites where AR typically binds with low affinity and is not 
transcriptionally active. Importantly, the gained AR sites observed under elevated FOXA1 
conditions contain both canonical forkhead and ARE motifs. When FOXA1 levels are 
increased, FOXA1 binds to these regions, making them more accessible in a greater 
proportion of the cells, resulting in an overall increase in AR binding. It is important to note 
that in the opposite condition, where FOXA1 is lost, AR is also reprogrammed (10, 21), but 
the novel AR binding sites that occur in the absence of FOXA1 are not the same as those 
that arise with over-expression of FOXA1. The simplest hypothesis for this difference is that 
in the absence of FOXA1, alternative transcription factors mediate AR binding to chromatin. 
In the presence of FOXA1, relative levels of this pioneer factor appear to be the rate-limiting 
determinant of AR chromatin binding in prostate cancer cells. Under conditions where 
FOXA1 is abnormally elevated, AR gains the capacity for enhanced chromatin binding at 
non-classical sites, as observed in CRPC. Intriguingly, these alterations in AR and FOXA1 
binding elicit a gene expression program that is reminiscent of that seen in CRPC primary 
tissues, which also exhibit high FOXA1 expression (15, 22). Resistance to ADT and 
progression to CRPC involves a diverse range of adaptive mechanisms to enhance AR 
signaling (4). Herein we provide evidence that one such mechanism could be via up-
regulation of FOXA1, resulting in an expanded AR chromatin binding landscape. Tumors 
with high FOXA1 levels may have greater intrinsic AR activity and therefore are better 
adapted to survive at low levels of androgen. The increased proliferation that ‘FOXA1 high’ 
cells exhibited with low androgen concentrations in our study supports this theory. Further 
in vivo investigation of the effect of increased FOXA1 levels on tumor growth is required. 
To date, two reports have been published investigating the effects of high FOXA1 levels on 
tumor growth, but the conclusions were inconclusive. The first of these studies concluded 
that elevated FOXA1 inhibit prostate cancer metastasis in an orthotopic mouse xenograft 
model (19). However, in that study, the AR negative PC3-M cell line, which is not 
representative of the vast majority of prostate tumors, including CRPC, was used as the 
experimental model, Another xenograft study that examined the consequence of FOXA1 
over-expression in AR+ LNCaP cells found a significant increase in tumor size compared to 
parental control cell xenografts (26), consistent with the results of the current study.
FOXA1 has been implicated as a marker of poor outcome in a number of tumor types, 
including lung (35), thyroid (36) esophageal (37) and malignant glioma (38). Our data 
supports the growing bank of evidence suggesting that FOXA1 is a marker of poor outcome 
in prostate cancer patients, where high expression levels correlate with a shorter time to 
biochemical relapse (15, 20, 22, 39). Furthermore, high FOXA1 expression robustly 
correlates with higher pathological stage, higher Gleason Score and AR expression (15, 20, 
21), implying a central role for FOXA1 in the progression of prostate cancer. In contrast, 
high FOXA1 mRNA levels correlate with better patient outcome measures, such as a longer 
time to biochemical recurrence (19, 40). A study of the concordance between changes seen 
by mRNA microarray analysis and of high-throughput proteomic profiling of primary 
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prostate cancer tissue showed only a 48% - 61% agreement (41). Given the role of FOXA1 
as a transcription factor that modulates chromatin accessibility and binding of other proteins, 
it is prudent to consider the correlations that occur with protein levels rather than mRNA 
levels.
The exact role that FOXA1 plays in CRPC is still unclear, but interestingly it was recently 
observed that FOXA1 is mutated in 3-5% of prostate cancers, suggesting that altered 
FOXA1 function may be a feature of CRPC (26, 42). Some in vitro data suggest that 
FOXA1 may not play an important part of the AR transcriptional complex in CRPC. Unique 
castration-resistant ARBS detected in the C4-2B cell line (23) do not significantly overlap 
with FOXA1 binding sites or contain the Forkhead motif. However, our results show that 
ablating FOXA1 in the C4-2B cell line robustly diminishes cell growth, indicating a 
persistent role for FOXA1. Additionally, our gene expression data for FOXA1 over-
expressing LNCaP cells correlated well with a published CRPC gene signature (24), 
indicating that FOXA1 may be an important player in the switch to a more aggressive gene 
expression profile like that seen in CRPC. Thus, it will be critical to map AR and FOXA1 
binding in matched primary and CRPC tissues in order to definitively assess the role of 
FOXA1 in prostate cancer progression.
In summary, FOXA1 is a key component of the AR transcription factor complex. High 
levels of FOXA1 result in increased AR binding, a transcription profile akin to CRPC and 
proliferation in the presence of low levels of androgenic hormones. These findings suggest a 
pivotal role for FOXA1 in the progression of prostate cancer.
Materials and methods
Cell Culture and Transfection
LNCaP and C4-2B prostate cancer and MDA-MB-453 breast cancer cell lines were grown 
in RPMI or DMEM media, respectively, supplemented with 10% FBS and standard 
antibiotics. For hormone deprivation conditions, phenol-red free RPMI or DMEM medium 
was supplemented with 5% charcoal dextran treated FBS. Cells were transfected with 3ug 
FOXA1 expression plasmid per 10cm dish using Lipofectamine 2000 (Invitrogen), 
according to manufacturer’s instructions. Full length FOXA1 cDNA was ligated into 
pcDNA3.1 (43). For FOXA1 knockdown experiments, C4-2B cells were transfected with 
50nM Allstars Negative Control siRNA (Qiagen) or a custom siRNA (Thermo Scientific) 
targeted to FOXA1 (GAGAGAAAAAAUCAACAGC) using Lipofectamine RNAiMAX 
(Invitrogen).
Cell growth assay
LNCaP and MDA-MB-453 cells were hormone deprived for two days then transfected with 
GFP or FOXA1 expression plasmid. The following day cells were trypsinised and re-plated 
at 4×103 (MDA-MB-453) or 5×103 (LNCaP) cells/well of 96 well plate in steroid free media 
and the next day cells were treated with 1nM DHT, 100nM DHT or vehicle control for 6 
days. The number of live cells was quantified at day 0 and day 6 using CellTiter-Blue assay 
(Promega) with 8 replicates per condition. Three independent experiments were performed. 
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C4-2B cells were plated at equal confluence and transfected with siControl or siFoxA1. The 
number of live cells was quantified using a hemocytometer after Trypan Blue staining at 
days 0, 4 and 7.
Western Blots
Whole cell lysate was extracted for western blots and protein quantified using Bradford 
assay. Antibodies used were anti-AR (sc-816) purchased from Santa Cruz Biotechnologies 
and anti-FOXA1 (ab5089) and anti-β-actin (ab6276) from Abcam. Secondary antibodies 
were used at a concentration of 1:2000.
Chromatin Immunoprecipitation coupled to high-throughput sequencing (ChIP-seq)
AR Chromatin immunoprecipitation (ChIP) experiments were conducted as described 
previously (44) using rabbit polyclonal anti-AR antibody (Santa Cruz Biotechnologies, 
sc-816). Briefly, 48 hours after transfection with GFP or FOXA1 expression plasmid cells 
were crosslinked with 1% formaldehyde and harvested. Cells were lysed, nucleus extracted 
and DNA sonicated using Diaganode Biorupter before immunopreciptation with AR 
antibody conjugated beads. Beads were thoroughly washed and reversed crosslinked at 65°C 
before amplification using TruSeq kit (Illumina). Single end 36-bp ChIP-seq data were 
generated by the Illumina analysis pipeline version 1.6.1, and reads were aligned to the 
Human Reference Genome (assembly hg19, GRCh37, Feb 2009) using bwa 0.5.9. Reads 
with MapQ scores less than 16 or falling within Duke’s Excluded Regions (45) were filtered 
from further analysis. Peaks were called using MACS, version 1.4.1. Heatmaps were created 
using python script as described in (46). For all ChIP-seq experiments, two biological 
replicates were performed and only reproducible peaks (i.e. those that occur in both 
replicates) were considered in downstream analysis if it occurred in both replicates. Motif 
analysis was performed using MEME-ChIP suite (47). Hierarchical clustering analysis of 
peaksets was performed using the DiffBind package (version 1.4.2) in Bioconductor version 
2.11 (48).
Rapid IMmunoprecipitation of Endogenous proteins (RIME)
LNCaP cells were crosslinked with 1% EM-grade formaldehyde for 7 min before they were 
harvested. RIME experiments were conducted as described in (28). Antibodies used for 
immunoprecipitation were anti-AR (sc-816), anti-rabbit IgG (sc-2027) and anti-goat IgG 
(sc-2028) from Santa Cruz Biotechnologies and anti-FOXA1 (ab5089) from Abcam. Mass 
Spectrometry was performed using LTQ Orbitrap Velos (Thermo Scientific).
Raw MS data files were processed using Proteome Discoverer v.1.3 (Thermo Scientific). 
Processed files were searched against the SwissProt human database using the Mascot 
search engine version 2.3.0, allowing up to one tryptic miscleavage and a tolerance on mass 
measurement of 10 ppm in MS mode and 0.6 Da for MS/MS ions. Identified proteins have 
at least 2 unique peptides and not occurred in any of the matched IgG samples. Pathway 
analysis of the common AR and FOXA1 partners was performed using GSEA molecular 
signature database tool version 3.1 (49) and STRING (version 9.05) produced the protein 
interaction network (50).
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Microarray Analysis
Cells were transfected with GFP or FOXA1 expression plasmid for 48h. RNA was collected 
from six biological replicates. The Illumina BeadChIP (HumanWG-12 version 4) bead-level 
data were preprocessed, log2-transformed, and quantile-normalised using the bead array 
package (51, 52) in Bioconductor (53). Differential expression analysis was performed using 
limma eBayes (Smyth 2004 with a Benjamini and Hochberg multiple test correction 
procedure (54) to identify statistically significant differentially expressed genes (FDR 0.05). 
GSEA molecular signature database tool version 3.1 (49) was used for pathway analysis of 
differentially expressed genes.
Patient Cohort
Full ethical approval was obtained for all human sample collections from Addenbrooke’s 
Hospital Research Ethics Committee (MREC 01/4/061). The tissue microarray (TMA) 
consisted of selected cores at least two distinct regions of tumor from each of the 102 men 
undergoing open radical retropubic prostatectomy. Matched cores from normal/benign 
regions (>3) were also taken as well as prostatic intraepithelial neoplasia (PIN) where 
available (55). We define biochemical recurrence (BCR) as a single PSA value of 
≥0.2ng/ml, with persistent elevation on subsequent PSA measurement. We included a 
“triggered treatment” group where the decision to initiate treatment with modalities such as 
radiotherapy occurred before the PSA value had reached this threshold. Time to relapse was 
calculated as the time from radical prostatectomy to first PSA of 0.2ng/ml or treatment, 
whichever occurred first.
Immunohistochemistry
Paraffin-embedded TMA blocks were freshly cut before immunohistochemistry which was 
performed on a Bond automated system (Leica). Primary goat anti-FOXA1 antibody 
(Abcam, ab5089), dilution 1:800 in Sanger diluent, was used with the F DABe protocol and 
Bond epitope retrieval solution 1 for 20min. Evaluation of the stained TMAs was 
undertaken by two independent observers, one of which was a specialized uropathologist 
(A.W.). Analysis was conducted using a multi-headed microscope and neither had any 
knowledge or information pertaining to the patient’s clinical status. Staining intensity for 
FOXA1 was evaluated on a four-tiered scale: 0 (negative), 1 (weak), 2 (moderate) and 3 
(strong) as well as percentage of nuclei stained. The resultant H-score incorporates both 
pieces of data (H-score = intensity X % positive stained cells).
Statistical analysis
In order to compare the difference in H-score between tumor and matched normal/benign, 
the Wilcoxon matched-pairs signed rank test was performed. To assess the effect of FOXA1 
expression on prostate cancer patient outcome, patients were divided into groups based on 
quartiles of their FOXA1 H-score, quartiles 2-4 were combined for analysis. The Kaplan-
Meier method was used to estimate the proportion of patients free of biochemical recurrence 
after radical prostatectomy, censoring at the last date of follow up. A univariable Cox 
proportional hazards regression model was used to evaluate the association between FOXA1 
staining and time to relapse. Clinical and pathological information was compared to FOXA1 
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staining using either a Mann-Whitney test for continuous data or Fisher’s exact test for 
categorical data.
Wilcoxon matched-pair signed rank test was used to assess of the significance in the average 
read count for AR ChIP-seq samples in control and ‘FOXA1 high’ cells. All other analyses 
unless stated were performed using unpaired Student’s T-Test or Fisher’s Exact Test. Only 
values with a p-value <0.05 were considered significant. Statistical analyses were performed 
using R Statistical software (version 2.14.0) or Graphpad Prism 6.
Data deposition
ChIP-seq sequencing data are available in the ArrayExpress database (www.ebi.ac.uk/
arrayexpress) under the accession number E-MTAB-1749. Microarray data has been 
deposited in the GEO database (accession number is pending).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. AR binding is enhanced in the presence of high levels of FOXA1
A. AR binding was mapped in FOXA1 over-expressing, ‘FOXA1 high’, versus Control 
transfected LNCaP cells using ChIP-seq. Venn diagram shows the overlap between the two 
datasets. B. Average binding intensity plot for AR ChIP-seq signal in control or ‘FOXA1 
high’ cells at all AR binding events, p value <0.0001. C. Average read count plot for AR 
ChIP-seq signal in control or ‘FOXA1 high’ cells at differentially bound regions. D. 
Heatmap of raw AR reads for ChIP-seq in control or ‘FOXA1 high’ cells at the AR binding 
sites (ARBS) shared or unique to ‘FOXA1 high’ cells. Black triangle denotes the summit of 
peak and a 10kb window surrounding the summit is shown. E. Genome browser snapshot 
showing AR ChIP-seq signal in control and ‘FOXA1 high’ cells in 1MB region of 
chromosome 11.
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Figure 2. AR may increase binding via its interactions with a number of chromatin remodelling 
proteins
A. Motif analysis of ARBS unique to ‘FOXA1 high’ cells reveals Forkhead, ARE, Stat and 
Ets motifs B. Overlap of ARBS shared or unique to ‘FOXA1 high’ cells with published 
FOXA1 ChIP-seq data (27), regions must overlap by at least 1 bp. C. Protein functional 
network of common AR and FOXA1 interacting proteins identified by proteomic profiling 
of the transcription factor complexes. Blue line denotes published evidence of interaction 
between two proteins and the width of the line is indicative of the confidence of the 
interaction.
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Figure 3. FOXA1 over-expression increases DHT stimulated growth in AR-driven cancers
CellTiter-Blue cell viability assay assessing the cell density of A. LNCaP prostate cancer 
and B. MDA-MB-453 breast cancer cell lines which were hormone deprived, transfected 
with GFP control or FOXA1 plasmids and then stimulated with low 0.5nM DHT or high 
100nM DHT levels of androgen. The data shown is an average of 8 replicates from one of 
three independent experiments, *** denotes p value <0.001. Error bars indicate standard 
deviations.
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Figure 4. FOXA1 expression correlates with poor outcome in prostate cancer
FOXA1 immunohistochemistry was performed on a prostate cancer TMA. For all sections, 
nuclei are shown in blue and FOXA1 staining in brown. Examples of staining criteria used 
are shown. A. Benign, B&C. Gleason Grade 3, D&E. Grade 4, F. Grade 5 Magnification is 
20X. G. Kaplan Meier survival curve indicating time to biochemical recurrence for patients 
with no/low FOXA1 staining (H score ≤4) or high FOXA1 staining (H-score 5-300). 
Survival information was available for 84 patients of whom 30 (36%) experienced 
biochemical recurrence.
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Figure 5. FOXA1 over-expression DEG correlate with CRPC gene expression program
A. Microanalysis of gene expression changes in LNCaP cells transfected with FOXA1 over-
expression plasmid for 48h. Only genes with an FDR <0.05 were considered which resulted 
in 124 FOXA1-high differentially expressed genes. B. The 124 FOXA1-high genes were 
analyzed for enriched biological pathways. C. Gene Set Enrichment analysis for genes 
determined in CRPC signature (24) using expression data from FOXA1 high LNCaPs. NES 
= Normalized Enrichment Score.
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Table 1
Association of FOXA1 Staining with Clinical Parameters
FOXA1 Low
(n=26)
FOXA1 High
(n=76)
p value
Age at surgery
(years)
62 (58-70) 63 (45-69) 0.523
Gleason Grade 0.247
    G6 14 (53.8%) 31 (40.8%)
    G7 11 (42.3%) 39 (51.3%)
    G8 1 (3.9%) 6 (7.9%)
Pathological Stage <0.0001
    T2 14 (73.7%) 30 (49.2%)
    T3 & T4 5 (26.3%) 31 (50.8%)
PSA at diagnosis
(ng/mL)
7.2 (3.9-16.2) 6.9 (2.1- 17.2) 0.273
Surgical Margins 0.021
    Clear 13 (68.4%) 24 (37.5%)
    Positive 6 (31.6%) 40 (62.5%)
Patients were divided into quartiles based on the FOXA1 H-score; first quartile = FOXA1 low, second, third and fourth quartiles = FOXA1 high. 
Median and range is given for age and PSA values. Information was unavailable for some patients regarding pathological stage (n=80), PSA (n= 
77) and surgical margins (n=83).
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